WEHI Partners with Parkinson's Research Foundation to Accelerate Drug Discovery for World's Fastest Growing Neurological Condition
Key Insights
The Walter and Eliza Hall Institute (search) (WEHI (search)) has formed a partnership with the Parkinson's Research Foundation (search) to accelerate drug discovery for Parkinson's disease (search), which affects over 200,000 Australians and is expected to double in the next 15 years.
WEHI (search)'s multidisciplinary research program focuses on boosting mitochondrial function as a potential disease-modifying therapy, building on breakthrough discoveries in cell death, ubiquitin (search) signaling, and genomics.
The venture philanthropy partnership aims to overcome the major cost barriers in translating research into clinical trials, with the shared goal of developing therapies that slow Parkinson's progression.
The Walter and Eliza Hall Institute (search) (WEHI (search)) has announced a strategic partnership with the Parkinson's Research Foundation (search) to intensify drug discovery efforts for Parkinson's disease (search), the world's fastest growing neurological condition. The collaboration aims to accelerate promising research projects toward clinical trials through venture philanthropy funding.
Addressing an Urgent Medical Need
Parkinson's disease (search) represents a growing global health crisis, ranking second only to Alzheimer's (search) in prevalence among neurological conditions. Over 200,000 Australians currently live with the debilitating condition, a figure projected to double within the next 15 years. The disease carries an estimated economic burden of over $12 billion annually in Australia alone.
The condition presents significant diagnostic and therapeutic challenges. No clinical diagnostic test exists, and there are currently no drugs available to slow disease progression. By the time most patients receive a diagnosis, more than 50% of dopamine-producing brain cells have already died. Patients often face years or even decades between their first symptoms and diagnosis, struggling with a complex array of symptoms that vary between individuals and fluctuate daily.
Venture Philanthropy Approach
The Parkinson's Research Foundation (search), founded by Richard Balanson and Michael Katz, brings a unique venture philanthropy model to medical research. Drawing from their experience in leading technology and financial companies, the founders focus on identifying key research areas where they can generate maximum impact through strategic funding and collaborative oversight.
"This project is just the beginning. We have an ambitious vision of a different way of supporting researchers with the aim of delivering results quicker, and the team at WEHI (search) fit that vision," said Richard Balanson, co-director of the Parkinson's Research Foundation (search).
The foundation's approach involves regular collaborative meetings to discuss strategic directions, moving beyond traditional funding models to actively engage in research acceleration.
Multidisciplinary Research Strategy
WEHI (search)'s Parkinson's Disease (search) Research Centre has developed a comprehensive research program targeting the fundamental drivers of the disease. The institute combines expertise in cell death, ubiquitin (search) signaling, mitochondrial functioning, and genomics—all interconnected pathways at the root of Parkinson's pathology.
Professor David Komander, head of WEHI (search)'s Ubiquitin (search) Signalling Division, explained the research focus: "Our research explores whether boosting the function of mitochondria (search), the powerhouses of cells, has potential as a disease-modifying therapy in Parkinson's. After this initial research phase, we will be able to accelerate to the next phase of drug discovery."
The research program builds on years of fundamental discoveries made by the WEHI (search) team, with multiple promising drug discovery projects now ready for acceleration toward clinical development.
Overcoming Translation Barriers
Professor Grant Dewson, head of the WEHI (search) Parkinson's Disease (search) Research Centre, identified cost as the primary obstacle in translating research discoveries into new therapies. "Research needs investment from partners like the Parkinson's Research Foundation (search) who are willing to commit to innovative new strategies that will drive transformative change," he said.
The partnership specifically addresses this challenge by providing sustained funding and strategic guidance to move promising discoveries through the expensive drug development pipeline. "Partnering with the Parkinson's Research Foundation (search) is about changing the lives of people with Parkinson's. Our shared goal is to have a drug therapy that slows the progression of Parkinson's in clinical trials as soon as possible," Dewson added.
Clinical Development Timeline
The collaboration represents a significant step toward addressing the urgent need for disease-modifying therapies in Parkinson's disease (search). With the foundation's venture philanthropy support, WEHI (search) aims to advance its most promising drug discovery projects through preclinical development and into clinical trials.
The partnership's success could establish a new model for accelerating medical research translation, potentially influencing how other neurological conditions are approached in drug development. As Parkinson's continues to grow as a global health challenge, this collaborative approach may prove crucial in developing the first therapies capable of slowing disease progression.